- Leveraging Predictive Biomarkers for Targeted Therapies in NSCLC
- Current and Emerging Biomarkers Predicting Response to Immune-Based Therapies to Guide Precision Treatment Decisions
- Best Practices for Sample Collection and Testing Methodologies
- Defining Optimal Workflows and Roles for Oncologists and Pathologists
- Interpreting Biomarker Assay Results for Therapeutic Planning
Date / Time
Matthew Gubens, MD
University of California, San Francisco
San Francisco, California
Lauren Ritterhouse, MD, PhD
Associate Director, Center for Integrated Diagnostics
Assistant Pathologist, Massachusetts General Hospital
Assistant Professor, Harvard Medical School
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and to plan individualized treatment for patients with lung cancer.
This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Apply new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
- Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
- Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
- Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
- Identify best practices and strategies for interdisciplinary collaboration/coordination among pathologists and oncologists, regarding cancer biomarker testing and interpretation of results to guide clinical decisions
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC point equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.